In vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: A retrospective analysis of results from five laboratories

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 2, 2006, Pages 713-723

  Beer, Brigitte E ^a   Doncel, Gustavo F ^b   Krebs, Fred C ^c   Shattock, Robin J ^d   Fletcher, Patricia S ^d   Buckheit Jr , Robert W ^e   Watson, Karen ^e   Dezzutti, Charlene S ^f,l   Cummins, James E ^a,f   Bromley, Ena ^g   Richardson Harman, Nicola ^g   Pallansch, Luke A ^a,m   Lackman Smith, Carol ^a   Osterling, Clay ^a   Mankowski, Marie ^a   Miller, Shendra R ^c   Catalone, Bradley J ^h,n   Welsh, Patricia A ^h   Howett, Mary K ⁱ   Wigdahl, Brian ^c   Turpin, Jim A ^j   Reichelderfer, Patricia ^k   more..

^a SOUTHERN RESEARCH INSTITUTE   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF LONDON   (United Kingdom)

^e ImQuest Biosciences   (United States)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^g BioStat Solutions Inc   (United States)

^h PENN STATE COLLEGE OF MEDICINE   (United States)

ⁱ DREXEL UNIVERSITY   (United States)

^j NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^k EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^l UNIVERSITY OF PITTSBURGH   (United States)

^m Cell Trends Inc   (United States)

ⁿ Olympus America Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MICROBICIDE; NONOXINOL 9;

ARTICLE; CELL LINE; CELL TYPE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IN VITRO STUDY; PRIORITY JOURNAL; REPRODUCIBILITY; RETROSPECTIVE STUDY;

ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS; CELL LINE; HIV-1; NONOXYNOL; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; VIRUS REPLICATION;

EID: 31944439679     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.2.713-723.2006     Document Type: Article

References (43)

1. Barnhart, K. T., A. Stolpen, E. S. Pretorius, and D. Malamud. 2001. Distribution of a spermicide containing nonoxynol-9 in the vaginal canal and the upper female reproductive tract. Hum. Reprod. 16:1151-1154.
2. Barre-Sinoussi, F., J. C. Chermann, F. Rey, M. T. Nugeyre, S. Chamaret, J. Gruest, C. Dauguet, C. Axler-Blin, F. Vezinet-Brun, C. Rouzioux, W. Rozenbaum, and L. Montagnier. 1983. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220:868-871.
3. Bourinbaiar, A. S., and S. Lee-Huang. 1994. Comparative in vitro study of contraceptive agents with anti-HIV activity: gramicidin, nonoxynol-9, and gossypol. Contraception 49:131-137.
4. Brambilla, D. 8 July 2002, posting date. VQA quantitative HIV RNA proficiency testing scoring criteria and policies. VQA RNA New Statistics Department. [Online.] http://aactg.s-3.com/pub/download/vir/VQA-RNA-PT -statistical-document.pdf.
5. Catalone, B. J., T. M. Kish-Catalone, L. R. Budgeon, E. B. Neely, M. Ferguson, F. C. Krebs, M. K. Howett, M. Labib, R. Rando, and B. Wigdahl. 2004. Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides. Antimicrob. Agents Chemother. 48:1837-1847.
6. Centers for Disease Control and Prevention. 4 August 2000, posting date. Letter from the director, National Center for HIV, STD, and TB Prevention. [Online.] http:/www.cdc.gov/hiv/pubs/mmwr/mmwr11aug00.htm.
7. Collman, R., J. W. Balliet, S. A. Gregory, H. Friedman, D. L. Kolson, N. Nathanson, and A. Srinivasan. 1992. An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1. J. Virol. 66:7517-7521.
8. Cook, R. L., and M. J. Rosenberg. 1998. Do spermicides containing nonoxynol-9 prevent sexually transmitted infections? A meta-analysis. Sex. Transm. Dis. 25:144-150.
9. Dezzutti, C. S., V. N. James, A. Ramos, S. T. Sullivan, A. Siddig, T. J. Bush, L. A. Grohskopf, L. Paxton, S. Subbarao, and C. E. Hart. 2004. In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission. Antimicrob. Agents Chemother. 48:3834-3844.
10. Distler, O., P. W. McQueen, M. L. Tsang, C. Byrne, B. A. Neilan, L. Evans, R. Penny, D. A. Cooper, and S. F. Delaney. 1995. Characterization of the V3 region of HIV-1 isolates from Sydney, Australia. AIDS Res. Hum. Retroviruses 11:423-425.
11. Fogh, J., W. C. Wright, and J. D. Loveless. 1977. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58:209-214.
12. Gartner, S., P. Markovits, D. M. Markovitz, M. H. Kaplan, R. C. Gallo, and M. Popovic. 1986. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 233:215-219.
13. Hermonat, P. L., R. W. Daniel, and K. V. Shah. 1992. The spermicide nonoxynol-9 does not inactivate papillomavirus. Sex. Transm. Dis. 19:203-205.
14. Hillier, S. L., T. Moench, R. Shattock, R. Black, P. Reichelderfer, and F. Veronese. 2005. In vitro and in vivo: the story of nonoxynol 9. J. Acquir. Immune Defic. Syndr. 39:1-8.
15. Gayle H. D., and G. L. Hill. 2001. Global impact of human immunodeficiency virus and AIDS. Clin. Microbiol. Rev. 14:327-335.
16. Jennings, C., D. Brambilla, and J. Bremer. 2002. Ratio of two successive optical densities from the Roche HIV-1 Monitor Test as a measure of accuracy of estimates of human immunodeficiency virus RNA concentration. J. Clin. Microbiol. 40:1067-1068.
17. Jennings, R., and A. Clegg. 1993. The inhibitory effect of spermicidal agents on replication of HSV-2 and HIV-1 in vitro. J. Antimicrob. Chemother. 32:71-82.
18. Jones, B. M., and L. M. Willcox. 1991. The susceptibility of organisms associated with bacterial vaginosis to spermicidal compounds, in vitro. Genitourin Med. 67:475-477.
19. Krebs, F. C., S. R. Miller, B. J. Catalone, R. Fichorova, D. Anderson, D. Malamud, M. K. Howett, and B. Wigdahl. 2002. Comparative in vitro sensitivities of human immune cell lines, vaginal and cervical epithelial cell lines, and primary cells to candidate microbicides nonoxynol 9, C31G, and sodium dodecyl sulfate. Antimicrob. Agents Chemother. 46:2292-2298.
20. Krebs, F. C., S. R. Miller, B. J. Catalone, P. A. Welsh, D. Malamud, M. K. Howett, and B. Wigdahl. 2000. Sodium dodecyl sulfate and C31G as microbicidal alternatives to nonoxynol 9: comparative sensitivity of primary human vaginal keratinocytes. Antimicrob. Agents Chemother. 44:1954-1960.
21. Krebs, F. C., S. R. Miller, D. Malamud, M. K. Howett, and B. Wigdahl. 1999. Inactivation of human immunodeficiency virus type 1 by nonoxynol-9, C31G, or an alkyl sulfate, sodium dodecyl sulfate. Antiviral Res. 43:157-173.
22. Kreiss, J., E. Ngugi, K. Holmes, J. Ndinya-Achola, P. Waiyaki, P. L. Roberts, I. Ruminjo, R. Sajabi, J. Kimata, T. R. Fleming, et al. 1992. Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA 268:477-482.
23. Kuramoto, H. 1972. Studies of the growth and cytogenetic properties of human endometrial adenocarcinoma in culture and its development into an established line. Acta Obstet. Gynaecol. Jpn. 19:47-58.
24. Leibovitz, A., J. C. Stinson, W. B. McCombs III, C. E. McCoy, K. C. Mazur, and N. D. Mabry. 1976. Classification of human colorectal adenocarcinoma cell lines. Cancer Res. 36:4562-4569.
25. Louv, W. C., H. Austin, W. J. Alexander, S. Stagno, and J. Cheeks. 1988. A clinical trial of nonoxynol-9 for preventing gonococcal and chlamydial infections. J. Infect. Dis. 158:518-523.
26. Mishra, S. 1997. The female condom: expanding contraceptive options. Manushi 99:37-38.
27. Niruthisard, S., R. E. Roddy, and S. Chutivongse. 1992. Use of nonoxynol-9 and reduction in rate of gonococcal and chlamydial cervical infections. Lancet 339:1371-1375.
28. Otto, M. J., S. Garber, D. L. Winslow, C. D. Reid, P. Aldrich, P. K. Jadhav, C. E. Patterson, C. N. Hodge, and Y. S. Cheng. 1993. In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease. Proc. Natl. Acad. Sci. USA 90:7543-7547.
29. Patton, D. L., Y. T. Cosgrove Sweeney, L. K. Rabe, and S. L. Hillier. 2002. Rectal applications of nonoxynol-9 cause tissue disruption in a monkey model. Sex. Transm. Dis. 29:581-587.
30. Patton, D. L., G. G. Kidder, Y. C. Sweeney, L. K. Rabe, A. M. Clark, and S. L. Hillier. 1996. Effects of nonoxynol-9 on vaginal microflora and chlamydial infection in a monkey model. Sex. Transm. Dis. 23:461-464.
31. Phillips, D. M., K. M. Sudol, C. L. Taylor, L. Guichard, R. Elsen, and R. A. Maguire. 2004. Lubricants containing N-9 may enhance rectal transmission of HIV and other STIs. Contraception 70:107-110.
32. Roddy, R. E., L. Zekeng, K. A. Ryan, U. Tamoufe, S. S. Weir, and E. L. Wong. 1998. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N. Engl. J. Med. 339:504-510.
33. Singh, B., J. C. Cutler, and H. M. Utidjian. 1972. Studies on development of a vaginal preparation providing both prophylaxis against venereal disease, other genital infections and contraception. III. In vitro effect of vaginal contraceptive and selected vaginal preparations of Candida albicans and Trichomonas vaginalis. Contraception 5:401-411.
34. Singh, B., J. C. Cutler, and H. M. Utidjian. 1972. Studies on the development of a vaginal preparation providing both prophylaxis against venereal disease and other genital infections and contraception. II. Effect in vitro of vaginal contraceptive and non-contraceptive preparations on Treponema pallidum and Neisseria gonorrhoeae. Br. J. Vener. Dis. 48:57-64.
35. Singh, B., B. Posti, and J. C. Cutler. 1976. Virucidal effect of certain chemical contraceptives on type 2 herpesvirus. Am. J. Obstet. Gynecol. 126:422-425.
36. Stafford, M. K., H. Ward, A. Flanagan, I. J. Rosenstein, D. Taylor-Robinson, J. R. Smith, J. Weber, and V. S. Kitchen. 1998. Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 17:327-331.
37. Sykes, J. A., J. Whitescarver, P. Jernstrom, J. F. Nolan, and P. Byatt. 1970. Some properties of a new epithelial cell line of human origin. J. Natl. Cancer Inst. 45:107-122.
38. Van Damme, L. 2004. Clinical microbicide research: an overview. Trop. Med. Int. Health 9:1290-1296.
39. Van Damme, L., G. Ramjee, M. Alary, B. Vuylsteke, V. Chandeying, H. Rees, P. Sirivongrangson, L. Mukenge-Tshibaka, V. Ettiegne-Traore, C. Uaheowitchai, S. S. Karim, B. Masse, J. Perriens, and M. Laga. 2002. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 360:971-977.
40. Ward, H., A. De La Court, and V. Kitchen. 1996. Nonoxynol-9 in lubricated condoms. Results of a study in female prostitutes. Sex. Transm. Dis. 23:413-414.
41. Weller, S. C. 1993. A meta-analysis of condom effectiveness in reducing sexually transmitted HIV. Soc. Sci. Med. 36:1635-1644.
42. Yen-Lieberman, B., D. Brambilla, B. Jackson, J. Bremer, R. Coombs, M. Cronin, S. Herman, D. Katzenstein, S. Leung, H. J. Lin, P. Palumbo, S. Rasheed, J. Todd, M. Vahey, and P. Reichelderfer. 1996. Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group virology laboratories. J. Clin. Microbiol. 34:2695-2701.
43. Zekeng, L., P. J. Feldblum, R. M. Oliver, and L. Kaptue. 1993. Barrier contraceptive use and HIV infection among high-risk women in Cameroon. AIDS 7:725-731.